Una vez más Genentech hace esfuerzos para oponerse a los reiterados intentos de Roche...
El tiempo (y el dinero) dirá quien puede más.
NEW YORK - Genentech Inc. on Monday urged its shareholders to reject a hostile buyout bid from Swiss drugmaker Roche.
A Genentech committee said the offer is inadequate and not in the best interest of stockholders.
Roche owns 56 percent of Genentech and is looking to buy the rest of the company for $42 billion, or $86.50 per share. The deal would need support from a majority of the other shareholders.
Entradas
No hay comentarios:
Publicar un comentario